Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone response prognostic model in short stature children (multicenter cohort)
ChiCTR2400088204Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Nanjing Medical University
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of somatropin in growth disorder, sponsored by Children's Hospital of Nanjing Medical University. Primary endpoint: Growth reaction (first-year Δheight SD). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
somatropin
03
Conditions
growth disorder
Beyond the preview
Go deeper on ChiCTR2400088204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088204.